Ixabepilone is a semisynthetic epothilone-B analogue, targeting microtubule structures in mitosis analog, that can be used after anthracycline and taxane treatment in patients with metastatic breast cancer. We aimed to analyze the results of ixabepilone and ixabepilone-capecitabine combination in heavily pretreated metastatic breast cancer patients. In this single-center study, records of 24 patients with hormone receptor positive and HER negative or triple negative metastatic breast cancer who received at least one cycle of ixabepilone or ixabepilone-capecitabine in our clinic between 2015 and 2019 were analyzed retrospectively. Kaplan-Meier survival analysis was used for progression-free survival (PFS), and overall survival (OS) analyzes. A total of 24 patients with metastatic breast cancer were eligible and included. The median age of the patients was 53.6 (range 33.7-77.3). Patients were heavily pre-treated with a range of 3-6 previous chemotherapy lines before ixabepilone. At the and of the follow up-up period (September 2019) all patients received a median of 4.5 cycles of ixabepilone. Partial response (PR) was achieved in 8 patients (33%) and stable disease (SD) was achieved in 7 patients (29%). Median PFS was 3.9 (95% CI: 3.4-5.6) months. The overall median PFS was 3.9 months, 4.0 months in hormone receptor-positive patients and 3.7 months in triple-negative patients. There was no statistically significant difference between histological subtypes in terms of PFS (p= 0.77). The most common grade 3-4 adverse events were neutropenia (n=11, 45,8%) and neuropathy (n=15, 62.5%). Ixabepilone only or combination with capecitabine may be considered as an effective treatment option for heavily pre-treated patients with metastatic breast cancer, regard to its side effects.